Search Results
Sep 08, 2025, 20:04 ET AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato oncology,
More news about: Amgen
Sep 08, 2025, 12:10 ET AAVivo, Inc. to Present Precision AAV Capsid Engineering (PACE) Platform for In Vivo CAR-T Therapy at BIOHK2025
Capsid Engineering Platform Enabling In Vivo CAR-T Therapy and Precision Gene Delivery," Dr. Chen will discuss AAVivo's PACE platform, which enables the transformation of non-targeted AAV vectors into precise and cell specific gene delivery vectors. PACE is a core component of AAVivo's IntelligentAAV
More news about: AAVivo, Inc.
Sep 08, 2025, 10:33 ET Liquid Biopsy Market to Reach USD 30.65 Billion by 2035, with CAGR 9.41% Driven by Rising Cancer Burden and Demand for Non-Invasive Diagnostics - Vantage Market Research
SelectionTreatment MonitoringRecurrence MonitoringBy Technology Multi-Gene Parallel Analysis using NGS (76.2%)Single-Gene Analysis using PCR MicroarraysBy Application Cancer Applications (85.1%)
More news about: Vantage Market Research
Sep 08, 2025, 10:28 ET August in Review: 12 Top Technology Press Releases
Hopewell Facility to Advance Gene Therapy Development and Manufacturing The strategic expansion is designed to meet growing industry demand for high-quality viral vector production and reflects ProBio's ongoing commitment to supporting the advancement of life-changing gene therapies.
More news about: PR Newswire
Sep 08, 2025, 09:00 ET Matica Biotechnology and Cirsium Biosciences Announce AAV Manufacturing Collaboration
Collaboration integrates breakthrough plant-based technology with downstream and analytical expertise to support innovation in gene therapy manufacturing COLLEGE STATION, Texas and SAN
More news about: Matica Biotechnology, Inc.
Sep 08, 2025, 09:00 ET Passport Shares Top Parking Violations Across U.S. Cities, Offering New Insight Into Curbside Behavior
goes beyond payment and citation counts, it provides a dynamic view of how people move through and interact with cities," said Gene Rohrwasser, CTO of Passport. "With our platform, cities can shift from reactive enforcement to proactive curb management, making streets safer
More news about: Passport
Sep 08, 2025, 09:00 ET BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
Achondroplasia Achondroplasia, the most common form of skeletal dysplasia, is characterized by impaired bone growth caused by a change in the FGFR3 gene. Bone growth is regulated by multiple biological processes including signaling pathways through fibroblast growth factor (FGF, which slows bone growth)
More news about: BioMarin Pharmaceutical Inc.
Sep 08, 2025, 08:49 ET Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
Cell Therapy Innovation for Comprehensive Sector InsightsLatest Progress and Future Outlook in Gene Therapy and mRNAFrom Lab to Patient: Overcoming CMC Barriers in Cell and Gene Therapy ManufacturingInnovation and Investment for CGTIn today's rapidly evolving CGT
More news about: GenScript Biotech Corporation
Sep 08, 2025, 08:30 ET CGT Oncology Trials: IRB/IBC Strategies, Trends and Operational Insights, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into proven IRB/IBC strategies that streamline regulatory compliance and keep cell and gene therapy (CGT) oncology trials moving forward without costly delays. The featured speakers will unlock insights into emerging operational trends shaping today's CGT landscape,
More news about: Xtalks
Sep 08, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Sep 08, 2025, 08:00 ET Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar
(NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and
More news about: Klotho Neurosciences, Inc.
Sep 08, 2025, 08:00 ET AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
cardiomyopathy (ACM), a broader condition that can also affect the left ventricle or both ventricles. "In preclinical studies, insertion of human ARVC gene mutations into mice reproduced all the major signs and symptoms of the disease," said Dr. Jason Roberts, principal investigator
More news about: AMO Pharma Limited
Sep 08, 2025, 08:00 ET AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
cardiomyopathy (ACM), a broader condition that can also affect the left ventricle or both ventricles. "In preclinical studies, insertion of human ARVC gene mutations into mice reproduced all the major signs and symptoms of the disease," said Dr. Jason Roberts, principal investigator
More news about: AMO Pharma Limited
Sep 08, 2025, 03:41 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
characterized by a wide range of cognitive and behavioral challenges. It is the most common genetic cause of intellectual disability and the leading single-gene form of autism spectrum disorder (ASD), affecting approximately 1 in 7,000 males and 1 in 11,000 females globally. There are currently no approved treatments
More news about: Servier
Sep 08, 2025, 03:39 ET Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
characterized by a wide range of cognitive and behavioral challenges. It is the most common genetic cause of intellectual disability and the leading single-gene form of autism spectrum disorder (ASD), affecting approximately 1 in 7,000 males and 1 in 11,000 females globally. There are currently no approved treatments
More news about: Servier
Sep 08, 2025, 03:00 ET ToolGen Files Patent Infringement Lawsuit Against Lonza in the Netherlands
Lonza Netherlands B.V., a contract development and manufacturing organization (CDMO) that produces CASGEVY, the world's first approved CRISPR-based gene therapy. The case was filed with the District Court of The Hague.
More news about: ToolGen
Sep 08, 2025, 02:00 ET A NEW ERA OF INNOVATION: STARS OF SCIENCE RETURNS FOR SEASON 17
Last year's winner, Yaman Tayyar from Syria, created 'Geno' - a device to help make gene therapy more accessible. Today, his startup, Prorenata Biotech, is now incubated
More news about: Stars of Science
Sep 08, 2025, 02:00 ET A NEW ERA OF INNOVATION: STARS OF SCIENCE RETURNS FOR SEASON 17
Last year's winner, Yaman Tayyar from Syria, created 'Geno' - a device to help make gene therapy more accessible. Today, his startup, Prorenata Biotech, is now incubated
More news about: Stars of Science
Sep 07, 2025, 22:00 ET Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
and histone modification. Unlike traditional gene-editing tools that rely on DNA cleavage, EPIREG™ offers a safer and revolutionary therapeutic approach for patients with chronic diseases, effectively mitigating safety concerns associated with conventional gene editing. Notably, Epigenic has independently
More news about: Epigenic Therapeutics
Sep 07, 2025, 14:26 ET Illumina® Protein Prep bringt neue Erkenntnisse aus der Proteomik für eine verbesserte Arzneimittelforschung und -entwicklung
das diagnostische Potenzial der Proteomik untermauert, die Erforschung seltener genetischer Krankheiten voranzutreiben, indem krankheitsassoziierte Gene und Signalwege aufgedeckt werden. „Der große Inhalt und die hohe analytische Sensitivität von Illumina Protein Prep ist ein großer Vorteil, um
More news about: Illumina, Inc.
Sep 05, 2025, 08:30 ET Advanced Therapy Safety Management: Proactive Strategies for Real-World Risk Detection, Upcoming Webinar Hosted by Xtalks
this free webinar, gain clinical insight into the long-term safety monitoring of advanced therapies through case examples of CAR-T and other cell and gene therapies. The focus will be on managing immune-related toxicities, interpreting real-world safety signals and adapting follow-up strategies for diverse
More news about: Xtalks
Sep 05, 2025, 07:05 ET REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
AAV therapeutic for the treatment of boys with MPS II, designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the
More news about: REGENXBIO Inc.
Sep 05, 2025, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New
More news about: Insmed Incorporated
Sep 05, 2025, 04:46 ET Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value
candidate Pidnarulex(CX-5461) ina Phase 1b/2 clinical trial in patients with B-cell lymphoma subtypes that harbors MYC gene aberrations.
More news about: Senhwa Biosciences, Inc.
Sep 05, 2025, 04:09 ET Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy
MxV glycoprotein (MxV-G) and incorporates T-cell-specific targeting molecules. This innovative design enables the direct in vivo delivery of the CAR gene, potentially addressing key limitations of conventional CAR-T therapies, including lengthy, complex, and costly manufacturing. Capital Recognition:
More news about: Immunofoco